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1 | INTRODUCTION 
Schizophrenia (MIM 181500) is a heritable mental disorder with a lifetime risk of ~1%. The 
emerging genetic architecture points to a spectrum of risk variation from common variants, 
likely to have subtle effects on gene expression, to functionally deleterious variants. Analysis 
of common risk variants has identified 108 independent schizophrenia associated risk loci 
(median odds ratio [OR] = 1.08) (Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2014), which collectively explain a small fraction of genetic risk (Loh et al., 
2015). Analysis of rare copy number variants (CNVs) has identified a global enrichment of 
CNV burden in schizophrenia patients and eight individual risk loci reaching genome-wide 
significance (4 < OR < 68) (Marshall et al., 2017). The risk CNVs are rare, even in 
schizophrenia cases, and were identified by large case–control studies or meta-analyses of 
array based data (reviewed in Marshall et al., 2017). Such rare variants, having greater 
penetrance and a potentially clearer relationship to disease risk, may be most informative 
for functional follow-up studies (Karayiorgou, Flint, Gogos, Malenka, & Genetic and Neural 
Complexity in Psychiatry 2011 Working Group, 2012). 
 
Next-generation sequencing (NGS) has allowed the search for rare risk variants to extend to 
the exome and genome using both case–control and family-based designs. To date, genome 
sequencing has been limited to exploratory studies of multiplex families (Homann et al., 
2016). A number of reasonably large case–control exome sequencing studies have now 
been reported and have identified gene-disruptive and putatively protein-damaging ultra-
rare variants to be more abundant in cases than controls (Genovese et al., 2016). Initially, 
some small gene sets were thought highly enriched for rare disruptive variants (S. M. Purcell 
et al., 2014) but subsequent analyses suggest the enrichment is within a broader set of 
potentially synaptic genes. Results from the largest study to date, an analysis of 4,877 cases 
and 6,203 controls did not succeed in implicating any individual gene or risk variant after 
correction for multiple testing (Genovese et al., 2016). 
 
The association of schizophrenia with decreased fecundity has prompted the study of trios 
samples to detect de novo variants. Data from CNV studies support de novo variation as a 
contributing factor to the genetic etiology of schizophrenia (Rees, Moskvina, Owen, 
O'Donovan, & Kirov, 2011). This has been confirmed by exome sequencing in trios 
implicating genes involved in synaptic function and chromatin remodeling, but also 
suggesting shared pathophysiology with other neurodevelopmental disorders such as 
autism and intellectual disability (Fromer et al., 2014; McCarthy et al., 2014). But like the 
case–control studies, the trios studies did not specifically identify a new risk gene after 
multiple test correction. It took the novel combined analysis of case–control and trios 
exome data to identify SETD1A, a gene involved in chromatin remodeling, as a site of rare 
loss-of-function (LoF) variants increasing risk of schizophrenia after genome-wide correction 
(Singh et al., 2016). 
 
With limited numbers of trios available for analysis and case– control sequencing studies 
remaining very expensive, the study of identity-by-descent (IBD) segments in genome-wide 
association study (GWAS) data is an alternative method for finding rare risk variants for 
schizophrenia. IBD segments represent chromosomal regions that are inherited without 
recombination from a common ancestor, and a signature of their presence is strong linkage 
disequilibrium across the segment that can be detected in GWAS data (Hou et al., 2013). IBD 
methods have been successfully applied in founder populations to identify genes for both 
monogenic (Brooks et al., 2009) and complex disorders (Morrow et al., 2008). In outbred 
populations, IBD methods have been successfully applied to map genes for 
neurodevelopmental disorders using array-based single nucleotide polymorphism (SNP) 
data with follow-up Sanger sequencing (Ercan-Sencicek et al., 2010) and using exome 
sequencing data (Krawitz et al., 2010) but these studies used family-based samples. IBD 
methods have been applied to population-based GWAS data for multiple sclerosis but with 
limited success (Lin et al., 2013; Westerlind et al., 2015). 
 
Here, we detail a novel approach to rare risk variant detection in schizophrenia that 
combines IBD analysis of GWAS data and exome sequencing. We used IBD analysis of GWAS 
data from a homogeneous sample of Irish schizophrenia patients and controls (Irish 
Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2, 
2012) to search for shared haplotype segments in distantly related individuals and tested for 
haplotype segments that were more frequent in cases than controls. This approach 
identified a subset of key individuals to be sequenced and reduced the search space for mid 
to high effect rare variants that may have arisen de novo in more recent generations but 
have not been removed from the population by purifying selection (Lupski, Belmont, 
Boerwinkle, & Gibbs, 2011). After exome sequencing haplotype carriers, we investigated 
these segments to identify rare and potentially functional coding variants and then tested 
these variants for association in both our Irish and large international case–control samples. 
 
 
2 | MATERIALS AND METHODS 
 
2.1 | Discovery sample 
The discovery sample included cases and controls from the Irish Schizophrenia Genomics 
Consortium/WTCCC2 GWAS study, which has previously been described (Irish Schizophrenia 
Genomics Consortium and the Wellcome Trust Case Control Consortium 2, 2012). 
Cases were recruited through community mental health services and inpatient units in the 
Republic of Ireland and Northern Ireland following similar research protocols and with local 
ethics approval. All participants were interviewed using a structured clinical interview 
(Structured Clinical Interview for DSM-III-R, Structured Clinical Interview for DSM-IV [First, 
Spitzer, Robert, Gibbon, & Williams, 2002]; Schedule for Affective Disorders and 
Schizophrenia [Lifetime Version; Endicott & Spitzer, 1978]; or Schedule for Clinical 
Assessment in Neuropsychiatry [World Health Organization, 1992]). Diagnosis of a major 
psychotic disorder was made by the consensus lifetime best estimate method using DSM-III-
R or DSM-IV criteria with all available information (interview, family or staff report, and 
chart review). All cases were over 18 years of age, were of Irish origin (being of Irish parents 
and having all four grandparents born in Ireland or the United Kingdom), and had been 
screened to exclude substance-induced psychotic disorder or psychosis due to a general 
medical condition. The final analysis included samples from 1,635 participants whose SNP 
data passed quality control filters, described below, and met DSM-IV criteria for 
schizophrenia (or a related disorder). 
 
Control individuals were ascertained with written informed consent from the Trinity 
Biobank and represented blood donors from the Irish Blood Transfusion Service recruited in 
the Republic of Ireland. They met the same ethnicity criteria as cases but were not 
specifically screened for psychiatric illness. Individuals taking regularly prescribed 
medication are excluded from blood donation in Ireland and donors are not financially 
remunerated. As the lifetime prevalence of schizophrenia is relatively low (<1%) and there 
was no obvious reason for individuals with schizophrenia to be overrepresented in the 
control subjects, the fraction of putative case individuals in the control collection was 
expected to be small. Following quality control (QC), the control sample included 1,838 
participants. 
 
2.2 | Replication samples 
GWAS data from 41 schizophrenia studies was accessed through the Psychiatric Genomics 
Consortium (PGC2 data) and a description of the individual datasets (which are based on 
individuals from Europe, North America, Australia and Asia, and genotyped on a variety of 
arrays) can be found in the 2014 PGC2 publication (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). Where possible, variants of interest were imputed 
in these datasets (maximum possible sample: 28,918 cases and 35,910 controls). A further 
independent replication dataset from the U.K. comprised 5,585 cases from two collections, 
Cardiff COGS and CLOZUK, and 8,103 controls from the U.K. Blood Service donors and the 
1958 British Birth Cohort. Samples were genotyped using the Illumina HumanExome and 
HumanOmniExpressExome BeadChip arrays, as described by Richards et al. (2016). 
 
2.3 | Discovery GWAS: Genotype calling 
All samples were genotyped using the Affymetrix 6.0 platform totalling 893,634 autosomal 
SNPs, either at the Affymetrix (Santa Clara, CA) or Broad Institute (Cambridge, 
Massachusetts) laboratories. For all samples passing laboratory quality control, raw 
intensities (from the .CEL files) were renormalized within collections using CelQuantileNorm 
(http:// outmodedbonsai.sourceforge.net/). These normalized intensities were used to call 
genotypes with an updated version of the Chiamo software 
(https://mathgen.stats.ox.ac.uk/genetics_software/chiamo/chiamo.html), adapted for 
Affymetrix 6.0 SNP data. 2.4 | Discovery GWAS: Quality control The primary GWAS has 
previously been reported and details of the original quality control methods were described 
therein (Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control 
Consortium 2, 2012). For this analysis, SNP data was subjected to additional quality filters 
(variants with minor allele frequency < 0.001, SNP missingness ш0.02, Hardy–Weinberg 
equilibrium p ч 10−6 were removed). SNP positions were updated to hg19. As the aim of 
this study was to identify shared regions of IBD between distantly related individuals, the 
previous stringent control on cryptic relatedness was relaxed such that the proportion of 
genome sharing between any possible pair of individuals was <0.1 (i.e., more distantly 
related than first cousins), rather than <0.05 as in the original study. In order to ensure a 
homogeneous sample, four individuals were removed that were identified as outliers in a 
multidimensional scaling analysis of pairwise genome-wide IBS distances (performed in 
PLINK [S. Purcell et al., 2007]). 
  
2.5 | Discovery GWAS: Identification of IBD segments 
IBD segments shared between pairs of individuals were detected using the Refined IBD 
algorithm (B. L. Browning & Browning, 2013) within BEAGLE 4.0 (r1230) (S. R. Browning & 
Browning, 2007). Candidate segments were required to have a minimum length of 1 cM and 
the likelihood ratio of an IBD model (one haplotype shared IBD) compared to a non-IBD 
model (no haplotypes shared IBD), that is, the logarithm of the odds (LOD) score, was 
required to be >3. These are the default values as implemented in (B. L. Browning & 
Browning, 2013). 
 
2.6 | Discovery GWAS: IBD mapping 
The efficient multiple-IBD (EMI) algorithm (Qian, Browning, & Browning, 2014) was used to 
identify clusters of individuals sharing a haplotype 
IBD. EMI was run using a window size of 200 kb and a cluster density of 0.5 (as in Qian et al., 
2014). IBD segments with LOD scores between 3 and 40 were weighted 0.8, IBD segments 
with LOD scores greater than 40 were weighted as 1. This resulted in a set of haplotype 
cluster files for each chromosome, detailing the genomic coordinates of each identified IBD 
segment (haplotype), and the individuals sharing each haplotype. Cluster files were 
converted to plink format for association testing. The association analysis was performed in 
PLINK (S. Purcell et al., 2007) and compared individual haplotype frequencies in cases versus 
controls. Haplotypes occurring significantly more frequently in cases than controls at p ч 
0.01 were taken forward for further analysis. A second strategy employed locus-based tests 
as opposed to the single haplotype tests performed previously. Each of the genomic regions 
containing multiple different IBD segments was considered a single locus, and the individual 
haplotypes within them were tested en masse using SKAT-O (Lee et al., 2012). Of the three 
significant loci detected at a family-wise error rate of 0.05, any individual haplotype within 
these loci more frequent in cases than controls at p ч 0.05 was taken forward for further 
analysis. For each of the 45 haplotype segments selected from the two strategies, and 
where DNA was available for at least two individuals sharing that haplotype, exome 
sequencing was performed on each individual. A total of 118 individuals were sequenced, 
representing 32 haplotype segments. 
 
2.7 | Exome capture and sequencing 
Exome capture was performed using the Solution Phase Exome Capture method, which is an 
optimization of the NimbleGen SeqCap EZ Library protocol and the BioO Scientific 
NEXTflex™ (Illumina Compatible, Austin, TX) Sequencing kit. (See technology note: Targeted 
Sequencing with NimbleGen SeqCap EZ Libraries and Illumina TruSeq DNA Sample 
Preparation kit.) Briefly, sonicated genomic DNA ranging from 1 to 5 μg was used to create 
Illumina Barcoded libraries. Approximately 1 μg of the precapture library was hybridized 
with the NimbleGen SeqCap EZ Human Exome Library v3.0 probes for 72 hr at 47 _C. (For 
further details see the NimbleGen SeqCap EZ Exome User's Guide and TechNote for paired-
end libraries.) Following dual capture, polymerase chain reaction (PCR) enrichment and QC 
evaluation, samples with Bioanalyzer traces resulting in broad peaks ranging from 250 to 
850 bp and producing the highest peak around 400 bp (DNA insert plus adaptors) were 
pooled (4–6 captures per pool). Libraries were sequenced on 1–2 lanes on a HiSeq 2000with 
a Paired End 101 run including a 9 bp index read for the barcode detection. 
 
2.8 | Data processing and variant calling 
Sequence reads from the Illumina HiSeq 2000 runs were de-multiplexed using the Illumina 
Casava v1.8 pipeline, aligned to hg19 using the BWA aligner (Li &Durbin, 2009), allowing 
twomismatches in the 30-base seed. Alignments were then paired, imported to binary 
(bam) format, sorted and indexed using SAMtools (Li et al., 2009). Picard was then used to 
fix anymate pair information altered by the sorting. Bamtools (Barnett, Garrison, Quinlan, 
Strömberg, & Marth, 2011) was used to filter alignments to retain only properly paired 
reads (reads alignedwith appropriate insert size and orientation). PCR duplicates were 
removed using Picard. Bamtools was then used to select alignments with a minimum 
mapping quality score of 20. Target coverage for each NimbleGen exome capture was 
assessed using Picard's HSmetrics utility, and both depth and breadth of coverage were 
reviewed for each sample. The Genome Analysis Toolkit (GATK v3.3; DePristo et al., 2011) 
was used for local read realignment around indels, and for base quality score recalibration 
using corrections for base position within the Illumina read, for sequence context, and for 
platform-reported quality. Variants were called using the GATK Haplotype Caller in joint 
calling mode, followed by Variant Quality Score Recalibration. Twelve sampleswere 
excluded due to lowcoverage. 
 
2.9 | Variant filtering and phasing 
The variant call format (VCF) file was filtered to retain variants passing variant quality 
recalibration and to ensure ш10× depth at the individual level (using vcftools [Danecek et al., 
2011]) and quality by depth ш5 at the variant level (using GATK [DePristo et al., 2011]). 
Samples were checked for concordance with GWAS data; all samples but one were >99% 
concordant for overlapping SNPs. The remaining discordant sample was determined to be a 
result of sample mix-up at the GWAS stage. Thus, sequence data was available for 105 
individuals, representing 32 individual haplotype segments. As the analysis is focused on 
variants shared IBD by at least two individuals, all singleton and private doubleton variants 
were excluded. Allele counts were updated and nonpolymorphic variants (postfiltering) 
removed. Variant IDs were updated to dbSNP142 rs# IDs where available (using SnpSift; 
Cingolani, Patel, et al., 2012). Variants were annotated with SnpEff (Cingolani, Platts, et al., 
2012) and the Variant Effect Predictor (VEP) (McLaren et al., 2010). The data was phased 
using Beagle 4.0 (r1230) and the haplotypes shared IBD between individuals, detected 
through the IBD mapping step, were identified. 
 
2.10 | Sanger sequencing 
Carriers of the PCNT variant rs143796569 (NC_000021.8:g.47817316G>A) identified through 
the exome study were Sanger sequenced (primer sequences are available on request) and 
all individuals were confirmed as heterozygotes. Selected individuals that were predicted to 
be carriers following imputation (see below) were also verified by Sanger sequencing.  
 
2.11 | Imputation 
The exome sequencing data was merged with existing GWAS data for the 105 sequenced 
individuals and the resulting dataset was used to create a reference panel using SHAPEIT v2 
(Delaneau, Marchini, & Zagury, 2012). This Irish reference panel was merged with the 1000 
Genomes Phase I integrated panel (December 2013 release; http:// 
www.internationalgenome.org/) and used to impute identified variants of interest into (a) 
the full Irish GWAS dataset and (b) individual PGC2 GWAS datasets. Association of variants 
with schizophrenia was tested using a score test implemented in SNPTEST v2 (Wellcome 
Trust Case Control Consortium, 2007). 
 
3 | RESULTS 
Figure 1 is a flow chart that summarizes the analytical methods used in this study. Seeking 
to identify relatively recent variants impacting on schizophrenia risk in a homogenous 
population, we performed IBD mapping using data generated from a previously published 
GWAS of Irish schizophrenia patients and controls (Irish Schizophrenia Genomics 
Consortium and the Wellcome Trust Case Control Consortium 2, 2012). We identified 
segments of the genome (>1 cM) predicted to be shared IBD between pairs of individuals 
using the Refined IBD algorithm within the Beagle software (B. L. Browning & Browning, 
2013). 
We subsequently performed clustering of the identified segments using the EMI algorithm 
(Qian et al., 2014) to identify haplotype segments shared by at least three individuals. As a 
result, 11,442 haplotype segments (each shared IBD between at least three people) were 
identified. 
 
For each of the 11,442 segments, the proportion of haplotype carriers in the patient group 
was compared with the proportion of haplotype carriers in the control group. Following 
correction for multiple testing, no individual haplotype segment was significantly associated 
with schizophrenia. However, as this was considered an exploratory analysis, 28 haplotype 
segments that were more frequent in cases than controls at uncorrected p ч 0.01 (listed in 
Supporting Information Table S1) were taken forward for further analysis. To capture the 
potential impact of multiple risk variants at a locus, multiple different IBD segments at a 
locus were collapsed and the individual haplotypes within them were tested en masse using 
SKAT-O (Lee et al., 2012). Forty loci were tested and three were significant after controlling 
for a family-wise error rate of 0.05 by resampling. Within these loci, 17 individual haplotype 
segments were observed more frequently in cases than controls at p ч 0.05 (listed in 
Supporting Information Table S1) and were taken forward for further analysis. In total, 45 
haplotype segments were selected for further analysis. 
 
Hypothesizing that rare haplotypes more frequently observed in cases than controls may 
harbor susceptibility variants of moderate to large effect, we focused on the coding 
sequence of the prioritized segments. Where DNA was available, we performed exome 
sequencing in carriers of the prioritized haplotypes (118 individuals). One hundred and five 
individuals passed quality control, allowing us to analyse 32 of the selected 45 haplotype 
segments (each with at least two carriers successfully sequenced). 
 
Of the identified sequence variants, those lying within haplotype segment regions were 
extracted and annotated with SnpEff and VEP. Initially high impact variants (e.g., frameshift, 
nonsense, splice site variants) that were either novel or with a minor allele frequency ч 0.01 
in public databases (1000 Genomes European population, the NHLBI GO Exome Sequencing 
Project [ESP; https://esp.gs.washington.edu/drupal/] European Ancestry population, the 
Exome Aggregation Consortium [ExAC; http://exac.broadinstitute.org/] European 
population) were assessed. However, of the 30 variants identified, none were carried by all 
sequenced members of a haplotype cluster. We then assessed moderate impact variants 
(e.g., missense variants, inframe indels) that were either novel or with a minor allele 
frequency ч 0.01 in public databases. Of the 159 moderate impact variants identified, three 
variants were carried by all sequenced members of a relevant haplotype cluster (Table 1). 
One of these variants was also carried by additional sequenced cases not identified in the 
original IBD analysis (see Table 1). Each variant was examined to determine if it was carried 
on the shared IBD haplotype identified in the original analysis. This was only the case for 
one of the variants; a rare, nonsynonymous variant in the PCNT gene, rs143796569 
(chr21:47817316G>A; hg19; NP_006022.3:p.Gly1452Arg), that was confirmed by Sanger 
sequencing. The variant causes a glycine to arginine change in the protein and is predicted 
to be ͞probably damaging͟ by Poly- Phen (Adzhubei et al., 2010) but ͞tolerated͟ by SIFT 
(Kumar, Henikoff, & Ng, 2009). Of the 11 cases and 1 control that were identified as sharing 
a haplotype at this locus, DNA was available for five individuals (all cases), which were 
sequenced; all five carried the alternate allele of the PCNT variant on the shared haplotype. 
The variant had been previously identified in other studies, with a minor allele frequency of 
0.0025 in 33,330 non-Finnish Europeans (ExAC), but was not observed in the 1000 
Genomes data. 
 
We used the exome and GWAS data of the 105 sequenced individuals, in conjunction with 
1000 Genomes data, to generate a merged reference panel in order to impute unobserved 
genotypes at the PCNT locus. The rs143796569 variant was successfully imputed in the 
original Irish GWAS data and predicted to be carried by all individuals sharing the haplotype 
segment; however, it was also predicted to be carried by several additional cases and 
controls. When tested for association with schizophrenia in the full GWAS sample, the minor 
allele of the imputed variant was present at a higher frequency in cases compared with 
controls, although this was not statistically significant (p = 0.057, OR = 1.77, 95%confidence 
interval [CI] = 0.98–3.17). 
 
The haplotype segment originally identified comprised 205 GWAS SNPs, covering almost 1 
Mb on chromosome 21 (chr21:47,013,876- 47,964,259; hg19). We investigated the 
haplotypes of the additional carriers of the rs143796569 rare allele identified through 
imputation and determined that these individuals all share a shorter, ~500 kb haplotype 
that is identical to the 30 end of the 1 Mb haplotype (chr21:47,503,311-47,964,259; hg19). 
Thus, while the rs143796569 rare allele is carried on the 1 Mb rare haplotype, it is not 
exclusive to it. 
 
We nevertheless sought to examine the rs143796569 variant in independent datasets. Using 
the 1000 Genomes/Irish merged reference panel, we attempted to impute the variant in 41 
GWAS datasets from the PGC2 schizophrenia study; the variant was successfully imputed 
(info > 0.5) and analyzed in seven datasets (see Table 2), comprising 6,889 cases and 8,043 
controls. Random effects meta-analysis of all seven datasets was not significant (p = 0.58, 
OR = 1.32, 95% CI = 0.49–3.59). We also assessed an independent dataset from the United 
Kingdom, in which the variant had been directly genotyped. Again, there was no evidence 
for association with schizophrenia (p = 0.32). 
 
 
FIGURE 1 Flow chart highlighting the methods used in our identity-by-descent (IBD) analysis 
of an Irish genome-wide association studies 
(GWAS) dataset. This study identified rs143796569 in PCNT as a putative rare risk variant for 
schizophrenia but subsequent analyses in 
independent case–control samples did not support association with schizophrenia 
 
4 | DISCUSSION 
We performed IBD mapping in an Irish schizophrenia GWAS dataset and selected 45 
genomic regions where a rare haplotype, >1 cM in length, was more frequent in cases 
compared to controls. For 32 of these regions, we were able to perform exome sequencing 
on at least two individuals that shared a rare haplotype. Using functional annotation tools 
and data on allele frequencies from a number of large-scale exome and genome sequencing 
projects, we examined these shared haplotypes for rare protein-altering variants that could 
increase risk of schizophrenia. We succeeded in identifying a single missense variant in PCNT 
that was present on a rare haplotype and more frequent in sequenced cases compared to 
controls. Using 1000 Genomes and our Irish exome sequencing data as a merged reference 
panel, we were able to impute this variant into our full Irish GWAS dataset; although the 
rare allele was more frequent in cases than controls, the test for association was not 
statistically significant (p = 0.057). Subsequent efforts in larger independent replication 
samples did not provide further support for association between this variant and 
schizophrenia. 
 
We consider two possible explanations for our findings in this region: (a) Our detection of 
the rare 1 Mb haplotype in 11 cases versus 1 control in our GWAS sample was a chance 
result and does not reflect a rare risk variant at this locus. This spurious association led us to 
the PCNT variant, which is not associated with schizophrenia. (b) This 1 Mb haplotype does 
carry a rare risk variant but it is not the PCNT variant and we could not find it using our 
approach here. When we imputed the PCNT variant into our GWAS sample, we found that it 
is not exclusively present on the 1 Mb haplotype. As such, if there is a rare risk variant on 
the 1 Mb haplotype that is responsible for the initial association signal after IBD analysis, it is 
not in complete linkage disequilibrium with the PCNT variant. Frustratingly, we could not 
find any variant, regardless of functional impact on coding sequence, in our exome data that 
was exclusive to and would effectively tag the 1Mb haplotype. Thus, we could test the PCNT 
variant in replication samples, but in the absence of a tagging variant we were not able to 
specifically test the 1 Mb haplotype itself for independent evidence of association with 
schizophrenia. 
 
While we have shown that this approach can identify rare risk haplotypes in GWAS data, the 
challenge in subsequent analysis of these haplotypes is that they are large, making the task 
of tagging them and pinpointing potential risk variants difficult. For the vast majority of the 
IBD haplotypes we found to be more frequent in cases compared to controls, we did not 
find a suitable variant to bring forward for association analysis. We concentrated on variants 
that we detected in coding sequences of genes via exome sequencing. The advantages to 
this approach were that we were better able to assess the functional impact of variants on 
protein coding genes and we could use large datasets from exome sequencing projects to 
measure the frequency of coding variants detected in European populations. It is possible 
that we missed functional variants in these haplotypes because they exist outside of coding 
regions or because they are difficult to detect using exome sequencing, for example, CNVs 
(Tan et al., 2014). Full analysis of the haplotypes using complete genome data would better 
capture all variants. Interpretation of these data will remain challenging until knowledge to 
support functional annotation of noncoding regions increases. Importantly, genome 
sequencing would provide a better opportunity to at least identify variants that exclusively 
tag rare risk haplotypes and can be used in replication association studies, even if the task of 
finding actual causal variants persists.  
As with any approach using GWAS data, larger sample sizes will provide more power to 
detect associations. An accurate IBD method for rare variant analysis of GWAS data is very 
appealing, as there are vast quantities of GWAS data available for re-analysis. The challenge 
is that these data were generated on numerous cohorts drawn from many diverse 
populations. IBD mapping is more effective in relatively homogeneous samples such as the 
Irish data used here. Increasing sample size means analysis of more heterogeneous samples, 
which can cause false-positive IBD mapping signals (S. R. Browning & Thompson, 2012). 
 
The availability of whole genome sequence data for a case– control sample would make IBD 
mapping irrelevant because the utility of identifying IBD segments is in their capacity to infer 
untyped variants, which would be present in sequence data (S. R. Browning & 
Thompson, 2012). At present however, the cost of genome sequencing has not dropped 
sufficiently to make this feasible. In the meantime, the application of IBD mapping to GWAS 
data warrants investigation. Our study was able to find large rare haplotypes that were 
significantly more frequent in cases compared to controls but full sequencing of the 
prioritized genomic segments rather than exome sequencing may have been more effective 
for mapping or tagging risk variants for replication analysis. 
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